title: A preliminary fluorodeoxyglucose positron emission tomography study in healthy adults reporting dream-enactment behavior.
abstract: OBJECTIVE
  To test the hypothesis that healthy adults reporting dream-enactment behavior (DEB+) have reduced cerebral metabolic rate for glucose (CMRgl) in regions preferentially affected in patients with dementia with Lewy bodies (DLB).
  
  
  METHODS
  Automated brain-mapping algorithms were used to compare regional fluorodeoxyglucose (FDG) positron emission tomography (PET) measurements from previously evaluated DEB cases and controls.
  
  
  METHODS
  Tertiary-care academic medical centers.
  
  
  METHODS
  Seventeen cognitively normal patients with DEB+ and 17 control subjects (DEB-) who were individually matched for age (59 +/- 11 years), education level (16 +/- 4 years), sex (67% women), body mass index (26 +/- 4.8 kg/m2), first-degree relative with dementia (85%), and proportion of apolipoprotein E (APOE) e4 carriers (13 e4 carriers, 4 noncarriers).
  
  
  METHODS
  FDG-PET.
  
  
  RESULTS
  DEB was associated with significantly lower CMRgl in several brain regions known to be preferentially affected in both DLB and Alzheimer disease (parietal, temporal, and posterior cingulate cortexes) and in several other regions, including the anterior cingulate cortex (p < .001, uncorrected for multiple comparisons). The DEB-associated CMRgl reductions were significantly greater in the APOE e4 noncarriers than in the carriers.
  
  
  CONCLUSIONS
  These preliminary findings suggest that cognitively normal persons with DEB have reduced CMRgl in brain regions known to be metabolically affected by DLB, supporting further study of DEB as a possible risk factor for the development of DLB.
authors.affiliation: Department of Neurology, Mayo Clinic, Scottsdale, Arizona 85259, USA. caselli.richard@mayo.edu
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Caselli
authors.forename: Kewei
authors.initials: K
authors.lastname: Chen
authors.forename: Dan
authors.initials: D
authors.lastname: Bandy
authors.forename: Oded
authors.initials: O
authors.lastname: Smilovici
authors.forename: Bradley F
authors.initials: BF
authors.lastname: Boeve
authors.forename: David
authors.initials: D
authors.lastname: Osborne
authors.forename: Gene E
authors.initials: GE
authors.lastname: Alexander
authors.forename: James M
authors.initials: JM
authors.lastname: Parish
authors.forename: Lois E
authors.initials: LE
authors.lastname: Krahn
authors.forename: Eric M
authors.initials: EM
authors.lastname: Reiman
mesh_terms: D000328:Adult; D000465:Algorithms; D053327:Apolipoprotein E4; D001057:Apolipoproteins E / Q000378:metabolism; D001921:Brain / Q000378:metabolism*; D001931:Brain Mapping; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D005500:Follow-Up Studies; D005947:Glucose / Q000378:metabolism; D006304:Health Status; D006801:Humans; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D012890:Sleep / Q000502:physiology*; D011795:Surveys and Questionnaires
chemical_list: D053327:Apolipoprotein E4; D001057:Apolipoproteins E; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D005947:Glucose